Sunshine Biopharma Stock Forecast

SBFM's stock price has decreased by -93.68% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Sunshine Biopharma stock has a target of 15, which predicts an increase of 880.39% from the current stock price of 1.53.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$15	$15	$15	$15
Change	+880.39%	+880.39%	+880.39%	+880.39%

* Price targets were last updated on Dec 5, 2024.

Analyst Ratings

According to 1 stock analyst, the rating for Sunshine Biopharma is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25
Strong Buy	1	1	1
Buy	0	0	0
Hold	0	0	0
Sell	0	0	0
Strong Sell	0	0	0
Total	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
David Bouchey Aegis Capital	Aegis Capital	Strong Buy Reiterates $15	Strong Buy	Reiterates	$15	+880.39%	Dec 5, 2024
David Bouchey Aegis Capital	Aegis Capital	Strong Buy Initiates $5,200	Strong Buy	Initiates	$5,200	+339,769.28%	Aug 7, 2023

More Analyst Ratings

Financial Forecast

Revenue This Year

102.00M

from 34.87M

192.48%

from 34.87M

Revenue Next Year

n/a

from 102.00M

EPS This Year

0.75

from -7.32

EPS Next Year

n/a

from 0.75

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025
Revenue	71.41K	228.43K	4.35M	24.09M	34.87M	102.00M
Revenue Growth	238.10%	219.88%	1,802.41%	454.42%	44.75%	192.48%
EPS	-	-	-	-351.35	-7.32	0.75
EPS Growth	-	-	-	-	-	-
Forward PE	-	-	-	-	-	2.03
No. Analysts	-	-	-	-	-	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025
High	105.0M
Avg	102.0M
Low	98.0M

Revenue Growth

Revenue Growth	2025
High	201.1%
Avg	192.5%
Low	181.0%

EPS Forecast

EPS	2025
High	0.78
Avg	0.75
Low	0.73

EPS Growth

EPS Growth	2025
High	-
Avg	-
Low	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.